Shares of Zymeworks Inc. (ZYME) are rising more than 10% Monday morning after reporting positive topline results from the Phase 2b study of zanidatamab in patients with biliary tract cancers.
Topline results from the Phase 2b HERIZON-BTC-01 study showed that 41.3% of enrolled patients with HER2-amplified and expressing disease achieved an objective response after treatment with zanidatamab.
Full results from the study are expected to be presented in 2023.
ZYME is at $7.17 currently. It has traded in the range of $4.11-$17.27 in the last 1 year.
Source: Read Full Article
Lates News:
-
Satoshi-Era Bitcoin Whale Moves $1.2 Million Worth Of BTC After 13 Years
-
Crypto Market Sentiment Muted Amidst Central Bank Reviews
-
Silo Pharma Soars On Positive Data For Its Arthritis Drug Candidate
-
Bitcoin And Ether Making A Major Bullish Turnaround, Trader Tells What To Expect
-
Teledyne Drops As Profit Outlook Comes In Below View

